AF
TERN

Amalgamated Financial’s Terns Pharmaceuticals TERN Stock Holding History

Amalgamated Financial’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$6K Buy
+2,079
New +$8.88K ﹤0.01% 2956

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Amalgamated Financial's TERN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Terns Pharmaceuticals (TERN) in Q1 2022: 2,079 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #2956 among its holdings.

44 funds tracked by Wall St. Rank hold TERN as of Q1 2022.

  • Amalgamated Financial held 2,079 shares of Terns Pharmaceuticals worth $6K as of Q1 2022.
  • Terns Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Terns Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2956 holding.
  • 44 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.